Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile

American Journal of Surgical Pathology

Volumn 27, Issue 2, 2003, Pages 159-166

  Hunt, Jennifer L ^a   LiVolsi, Virginia A ^b   Baloch, Zubair W ^b   Barnes, E Leon ^a   Swalsky, Patricia A ^a   Niehouse, Laura ^a   Finkelstein, Sydney D ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Loss of heterozygosity; Microcarcinoma; Papillary carcinoma; Thyroid; Tumor suppressor gene

Indexed keywords

ARTICLE; CANCER SIZE; CHROMOSOME MICRODISSECTION; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; GENE FREQUENCY; GENE MUTATION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; MICROSCOPIC ANATOMY; MOLECULAR GENETICS; PATHOGENESIS; PROGNOSIS; THYROID PAPILLARY CARCINOMA; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

CARCINOMA, PAPILLARY; DROSOPHILA PROTEINS; GENE FREQUENCY; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0037309279     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200302000-00003     Document Type: Article

References (26)

1. Bisi H, Ruggeri GB, Longatto Filho A, et al. Neoplastic and non-neoplastic thyroid lesions in autopsy material: historical review of six decades in Sao Paulo, Brazil. Tumori 1998;84:499-503.
2. Cady B, Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462-8.
3. Cheung CC, Carydis B, Ezzat S, et al. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 2001;86:2187-90.
4. Cohn KH, Backdahl M, Forsslund G, et al. Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy. Surgery 1984;96:957-71.
5. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000;7:229-39.
6. Fan CY, Liu KL, Huang HY, et al. Frequent allelic imbalance and loss of protein expression of the DNA repair gene of hOGG1 in head and neck squamous cell carcinoma. Lab Invest 2001;81:10.
7. Furlan JC, Bedard Y, Rosen IB. Biologic basis for the treatment of microscopic, occult well-differentiated thyroid cancer. Surgery 2001;130:1050-4.
8. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-56.
9. Harach HR, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999;3: 331-40.
10. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-64; discussion 964-6.
11. Lin JD, Chao TC, Chen ST, et al. Characteristics of thyroid carcinomas in aging patients. Eur J Clin Invest 2000;30:147-53.
12. Mai KT, Landry DC, Thomas J, et al. Ret oncogene protein expression in papillary thyroid carcinoma and related lesions. Tumori 2001;87:166-72.
13. Mazzaferri EL. Papillary and follicular thyroid cancer: selective therapy. Compr Ther 1981;7:6-14.
14. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7.
15. Nasir A, Chaudhry AZ, Gillespie J, et al. Papillary microcarcinoma of the thyroid: a clinico-pathologic and prognostic review. In Vivo 2000;14:367-76.
16. Neuhold N, Kaiser H, Kaserer K. Latent carcinoma of the thyroid in Austria: a systematic autopsy study. Endocr Pathol 2001;12: 23-31.
17. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 1989;64: 547-51.
18. Pomorski L, Bartos M. Metastasis as the first sign of thyroid cancer. Neoplasma 1999;46:309-12.
19. Rassael H, Thompson LD, Heffess CS. A rationale for conservative management of microscopic papillary carcinoma of the thyroid gland: a clinicopathologic correlation of 90 cases. Eur Arch Otorhinolaryngol 1998;255:462-7.
20. Sheils OM, Sweeney EC. Ret/PTC activation in Hashimoto's thyroiditis. Int J Surg Pathol 2001:8:185-9.
21. Sugg SL, Ezzat S, Rosen IB, et al. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998;83:4116-22.
22. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 1999;46:209-16.
23. Thiagalingam S, Foy RL, Cheng KH, et al. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr Opin Oncol 2002;14:65-72.
24. Van Deerlin VM, Leonard DG. Bone marrow engraftment analysis after allogeneic bone marrow transplantation. Clin Lab Med 2000; 20:197-225.
25. Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 1997;107:95-100.
26. Yamamoto Y, Maeda T, Izumi K, et al. Occult papillary carcinoma of the thyroid: a study of 408 autopsy cases. Cancer 1990;65: 1173-9.